De Brauw Blackstone Westbroek has assisted Pfizer Inc. on acquiring a USD 87.5 million minority equity interest in AM-Pharma, a privately held Dutch biopharmaceutical company and has secured an exclusive option to acquire the remaining equity in the company. AM-Pharma focuses on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases.

The option becomes exercisable upon completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury (AKI) related to sepsis. There are no drugs currently approved for this condition and the only treatment option is dialysis and supportive care. Results from the current Phase II trial for recAP are expected in the second half of 2016.

De Brauw Blackstone Westbroek acted as Dutch legal counsel to Pfizer, and Pierre Nijnens was lead partner. De Brauw worked alongside with Ropes & Gray, Pfizer's U.S. counsel.